Welcome to our dedicated page for Organogenesis Holdings SEC filings (Ticker: ORGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Organogenesis Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Organogenesis Holdings's regulatory disclosures and financial reporting.
Organogenesis Holdings Inc. director Arthur S. Leibowitz reported an open-market purchase of 5,000 shares of Class A common stock at a price of $2.681 per share on March 9, 2026. Following this transaction, his directly held stake increased to 291,014 shares.
Organogenesis Holdings Inc. director Michael Joseph Driscoll bought 10,000 shares of Class A Common Stock in an open-market purchase. He paid about $2.67 per share, for a total of roughly $26,688. Following this transaction, he directly owns 225,707 shares, making this a relatively small addition to his stake.
Organogenesis Holdings Inc. vice president of strategy Robert Cavorsi reported a tax-related share transfer. On this transaction, 700 shares of Class A common stock were disposed of at $3.21 per share to cover tax withholding obligations, leaving him with 275,524 directly held shares.
Organogenesis Holdings Inc. executive Antonio S. Montecalvo reported updated stock transactions related to an equity award. The amended filing corrects the number of Class A Common shares acquired upon vesting of a performance share award and the shares withheld to cover taxes. On February 18, 2026, he was granted 11,330 shares at a price of $0.00 per share and had 3,778 shares withheld at $3.84 per share to satisfy tax obligations. After these adjustments, he directly holds 226,238 Class A Common shares. The amendment states no other changes were made to the original report.
Organogenesis Holdings Inc. President and CEO Gary S. Gillheeney reported updated equity compensation activity. On February 18, 2026, he acquired 188,856 shares of Class A common stock as a grant or award at $0.00 per share, and disposed of 91,311 shares at $3.84 per share to cover tax obligations. The amendment corrects the numbers previously reported for the performance share vesting and related tax-withholding, with no other changes to the original Form 4.
Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow filed an amended insider transaction report. On February 18, 2026, he acquired 48,818 shares of Class A common stock at $0.00 per share through the vesting and settlement of a performance share award, and 11,887 shares were disposed of at $3.84 per share to cover tax obligations. After these adjustments, he directly owns 899,724 shares. The amendment corrects the previously reported share amounts related to this award, with no other changes.
Organogenesis Holdings Inc. Chief Operating Officer Patrick Bilbo filed an amended insider report updating a prior Form 4. The amendment corrects the number of Class A Common Stock shares reported from a performance share award that vested on February 18, 2026 and the related tax withholding. The filing now shows an award acquisition of 49,102 shares at a stated price of $0.00 per share and a tax-withholding disposition of 16,375 shares at $3.84 per share. Following these adjustments, Bilbo directly holds 1,128,312 shares of Class A Common Stock.
Organogenesis Holdings Inc. Chief Financial Officer Francisco David reported amended equity award details. On February 18, 2026, he acquired 44,040 shares of Class A common stock as a grant at no cost, and 14,687 shares were withheld at $3.84 per share to cover tax obligations. This amendment only corrects the share counts previously reported for the award vesting and related tax withholding.
Organogenesis Holdings Inc. executive Robert Cavorsi, Vice President of Strategy, filed an amended insider report updating a prior Form 4. The amendment corrects the number of Class A Common Stock shares acquired upon vesting and settlement of a performance share award and the shares withheld for taxes. On February 18, 2026, he was granted 16,454 shares at $0.00 per share and had 5,487 shares withheld at $3.84 per share to satisfy tax obligations. Following these adjustments, his direct holdings total 276,224 Class A shares. The filing states no other changes were made to the original report.
Organogenesis Holdings Inc. executive Lori Freedman updated her insider holdings following a performance share award. She acquired 43,212 shares of Class A common stock at no cost from the vesting and settlement of a performance share award, and 14,411 shares were withheld to cover related tax obligations. This amended Form 4 corrects the originally reported acquired and tax-withheld share amounts, with no other changes to the prior filing.